The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor

Cellular and Molecular Life Sciences

Volumn 68, Issue 14, 2011, Pages 2453-2467

  Montuori, Nunzia ^a   Bifulco, Katia ^b   Carriero, Maria Vincenza ^b   La Penna, Claudio ^a   Visconte, Valeria ^a   Alfano, Daniela ^c   Pesapane, Ada ^a   Rossi, Francesca Wanda ^a   Salzano, Salvatore ^d   Rossi, Guido ^a   Ragno, Pia ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d CNR   (Italy)

Author keywords

CXCR4; fMLP receptors; Prostate carcinoma cells; uPAR; Urokinase receptor

Indexed keywords

BETA1 INTEGRIN; CD51 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOTAXIS AFFECTING AGENT; COLLAGEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE RECEPTOR; RECEPTOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN; VITRONECTIN RECEPTOR;

ARTICLE; CELL ADHESION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INTERACTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIPID RAFT; MOLECULAR INTERACTION; NONHUMAN; PROSTATE CARCINOMA; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CHEMOKINE CXCL12; COLLAGEN; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; INTEGRIN ALPHA5BETA1; MEMBRANE MICRODOMAINS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTOR CROSS-TALK; RECEPTORS, CXCR4; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA INTERFERENCE; TRANSFECTION; VITRONECTIN;

EID: 79960946347     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0564-7     Document Type: Article

References (56)

1. Murdoch C (2000) CXCR4: chemokine receptor extraordinaire. Immunol Rev 177:175-184
2. Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14:171-179
3. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ (2005) Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23:879-894 (Pubitemid 41170944)
4. Zlotnik A (2006) Chemokines and cancer. Int J Cancer 119:2026-2029
5. Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107:1761-1767 (Pubitemid 43289351)
6. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y (1999) The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56:104-132 (Pubitemid 29471930)
7. Cunningham O, Andolfo A, Santovito ML, Iuzzolino L, Blasi F, Sidenius N (2003) Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J 22:5994-6003 (Pubitemid 37463243)
8. Viola A, Gupta N (2007) Tether and trap: regulation of membrane-raft dynamics by actin-binding proteins. Nat Rev Immunol 7:889-896 (Pubitemid 350006240)
9. Ragno P (2006) The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 63:1028-1037
10. Felding-Habermann B, Cheresh DA (1993) Vitronectin and its receptors. Curr Opin Cell Biol 5:864-868
11. Henry C, Moitessier N, Chapleur Y (2002) Vitronectin receptor alpha(V)beta(3) integrin antagonists: chemical and structural requirements for activity and selectivity. Mini Rev Med Chem 2:531-534
12. Montuori N, Ragno P (2009) Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci 14:2494-2503
13. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F (2002) The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/ LXA4R. Proc Natl Acad Sci USA 99:1359-1364 (Pubitemid 34136498)
14. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P (2002) The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 277:46932-46939 (Pubitemid 36159197)
15. Le Y, Murphy PM, Wang JM (2002) Formyl-peptide receptors revisited. Trends Immunol 23:541-548
16. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F (1997) A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16:7279-7286 (Pubitemid 28010488)
17. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P (2005) Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105:2198-2205 (Pubitemid 40731813)
18. Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, Grieco P, Peluso G, Stoppelli MP, Carriero MV (2005) Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem 280:25225-25232 (Pubitemid 40934616)
19. Furlan F, Orlando S, Laudanna C, Resnati M, Basso V, Blasi F, Mondino A (2004) The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci 117:2909-2916 (Pubitemid 39117666)
20. Li BQ, Wetzel MA, Mikovits JA, Henderson EE, Rogers TJ, Gong W, Le Y, Ruscetti FW, Wang JM (2001) The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1. Blood 97:2941-2947
21. Le Y, Shen W, Li B, Gong W, Dunlop NM, Wang JM (1999) A new insight into the role of "old" chemotactic peptide receptors FPR and FPRL1: down-regulation of chemokine receptors CCR5 and CXCR4. Forum (Genova) 9:299-314
22. Svensson L, Redvall E, Johnsson M, Stenfeldt AL, Dahlgren C, Wennerås C (2009) Interplay between signaling via the formyl peptide receptor (FPR) and chemokine receptor 3 (CCR3) in human eosinophils. J Leukoc Biol 86:327-336
23. Chigaev A, Waller A, Amit O, Halip L, Bologa CG, Sklar LA (2009) Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. J Biol Chem 284:14337-14346
24. Huang J, Chen K, Gong W, Dunlop NM, Wang JM (2008) G-protein coupled chemoattractant receptors and cancer. Front Biosci 13:3352-3363 (Pubitemid 351594687)
25. Selleri C, Montuori N, Ricci P, Visconte V, Baiano A, Carriero MV, Rotoli B, Rossi G, Ragno P (2006) In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. Cancer Res 66:10885-10890
26. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N (2007) uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 177:927-939 (Pubitemid 46873097)
27. Wolfenson H, Henis YI, Geiger B, Bershadsky AD (2009) The heel and toe of the cell's foot: a multifaceted approach for understanding the structure and dynamics of focal adhesions. Cell Motil Cytoskelet 66:1017-1029
28. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388
29. Yuan C, Huang M (2007) Does the urokinase receptor exist in a latent form? Cell Mol Life Sci 64:1033-1037
30. Gårdsvoll H, Ploug M (2007) Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem 282:13561-13572 (Pubitemid 47100512)
31. Ali H, Richardson RM, Haribabu B, Snyderman R (1999) Chemoattractant receptor cross-desensitization. J Biol Chem 274:6027-6030 (Pubitemid 29111002)
32. Rabiet MJ, Huet E, Boulay F (2007) The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 89:1089-1106 (Pubitemid 47260646)
33. Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, Stoppelli MP, Pavone V, Carriero MV (2008) An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett 582:1141-1146
34. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943 (Pubitemid 35477371)
35. Ossowski L, Aguirre-Ghiso JA (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12:613-620
36. Franco P, Vocca I, Carriero MV, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli MP (2006) Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin. J Cell Sci 119:3424-3434 (Pubitemid 44405226)
37. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP (1999) Urokinase receptor interacts with alpha(v)beta5 vitro-nectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 59:5307-5314 (Pubitemid 29503999)
38. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273:1551-1555 (Pubitemid 26301666)
39. Del Pozo MA (2004) Integrin signaling and lipid rafts. Cell Cycle 3:725-728
40. Lajoie P, Goetz JG, Dennis JW, Nabi IR (2009) Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol 185:381-385
41. Nguyen DH, Taub D (2002) CXCR4 function requires membrane cholesterol: implications for HIV infection. J Immunol 168:4121-4126 (Pubitemid 34298420)
42. Harburger DS, Calderwood DA (2009) Integrin signalling at a glance. J Cell Sci 122:159-163
43. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16:513-528 (Pubitemid 29009587)
44. Cannio R, Rennie PS, Blasi F (1991) A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene. Nucleic Acids Res 19:2303-2308 (Pubitemid 21902962)
45. de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V, Rossi G, Marone G, Ragno P (2004) Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J Immunol 173:5739-5748 (Pubitemid 39392163)
46. Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89-104
47. Luo BH, Carman CV, Springer TA (2007) Structural basis of integrin regulation and signaling. Annu Rev Immunol 25:619-647 (Pubitemid 46697919)
48. Degryse B, Resnati M, Czekay RP, Loskutoff DJ, Blasi F (2005) Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem 280:24792-24803 (Pubitemid 40934570)
49. Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski L (2006) A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J Biol Chem 281:14852-14863 (Pubitemid 43855190)
50. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ (2004) CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35:233-245 (Pubitemid 40585309)
51. Epstein RJ (2004) The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 4:901-909
52. Waugh DJ, Wilson C, Seaton A, Maxwell PJ (2008) Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 13:4595-4604 (Pubitemid 351589184)
53. Wong D, Korz W (2008) Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 14:7975-7980
54. de Bock CE, Wang Y (2004) Clinical significance of urokinasetype plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24:13-39
55. Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22:205-222 (Pubitemid 36561058)
56. Pillay V, Dass CR, Choong PF (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25:33-39 (Pubitemid 46001467)